After remaining largely unscathed by the global financial and eurozone debt crisis, the Cypriot banking sector succumbed to pressure in 2012 triggered by huge losses from investments in Greek sovereign and corporate bonds. The depressed economic environment led to a sharp decline in employment levels, leading to erosion in consumer confidence and spending. The recessionary economic conditions eroded demand for life insurance products with the segment’s gross written premium falling by 7.1% in 2012. The life segment accounted for the largest share with 39.7% of the written premium of the overall insurance industry in 2012.
Friday, March 28, 2014
The Cypriot reinsurance segment registered a compound annual growth rate (CAGR) of 8.1% during the review period (2008–2012). The primary application of reinsurance in Cyprus is to manage exposure to weather-related events. Although not particularly vulnerable to natural disasters, Cyprus is highly exposed to floods, storms, extreme temperatures and earthquakes. The majority of reinsurance revenues are generated from the non-life segment, which ceded an average of 35.0% of its written premium during the review period, compared with 11.8% and 24.8% for the life and personal accident and health segments.
Thursday, March 20, 2014
Market Research Reports.Biz announces addition of new report “ Pharmaceutical Market ” to its database.
Visit Same Publisher Report: The Pharmaceutical Market: Russia, Spain, United Kingdom, India, Finland
Both domestic and cross-border mergers and acquisitions (M&A) activity has picked up since the 2009 economic crisis, a result of increased incentives for local production under the government's industrial policy for the sector and the need for scale to compete , especially in the generic medicines market. We believe a critical forward step for the market will be the successful implementation of a broad-based medicines insurance programmer in the next few years, following current pilot projects. If this proves successful, we would expect growth to outstrip our current five-year projection for a compound annual growth rate of 8.3% in US dollar terms during the period 2012-2017.
For More Latest Reports Under the Same Category: Pharmaceutical Market
Headline Expenditure Projections
Pharmaceuticals: RUB664.72bn (US$20.96bn) in 2012 to RUR728.00bn (US$22.40bn) in 2013; +9.5% in local currency terms and 6.9% in US dollar terms. Forecast is virtually unchanged from Q412.
Healthcare: RUB2,709.62 (US$85.42bn) in 2012 to RUB2928.54bn (US$90.11bn) in 2013; +8.1% in local currency terms and +5.5% in US dollar terms. Forecast is virtually unchanged from Q412.
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
Table of Content
Russia, Spain, United Kingdom, India, Finland Pharmaceuticals And Healthcare Industry SWOT
Russia, Spain, United Kingdom, India, Finland Political SWOT
Russia, Spain, United Kingdom, India, Finland Economic SWOT
Russia, Spain, United Kingdom, India, Finland Business Environment SWOT
Pharmaceutical Risk/Reward Ratings
Table: CEE Pharmaceutical Risk/Reward Ratings, Q213
Berlin-Chemie/Menarini Pharma GmbH
Market Research Reports.biz is the most comprehensive collection of market research reports. Market Research Reports.biz services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
90 Sate Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: +1-866-997-4948
Browse Market Research Blog:
Blog: Markets News